Project description
Insensitive mice may elucidate a path to relief for chronic pain
Estimates suggest that at least one in five people globally suffer from chronic pain. Aside from impairing a person's ability to perform activities of daily living, chronic pain can lead to a chronic stress reaction. This can increase blood pressure and heart rate and result in other harmful effects on health including reduced immunity to illnesses and diseases. Knockdown of a specific gene in mice leads to reduced sensitivity to pain, and researchers have now identified several existing drugs that could mimic this effect. EU funding of the ChronicPain project is helping these researchers exploit their discovery, using it to test approved and candidate drugs on the path to relief for millions of people suffering with chronic pain.
Objective
Chronic pain is one of the most significant unmet medical needs and health burdens in society today. This is due to limited analgesic efficacy of existing drugs, coupled with adverse side effects, and the development of tolerance over time. Moreover, patients may develop dependence on commonly prescribed opiate-based analgesics, with negative consequences and greatly increased societal costs. Hence there is a pressing need for new targets for drug development and new drug candidates to target chronic pain.
During the course of our recently completed ERC grant we screened a number of mouse mutants for sensory neuron phenotypes that might arise from perturbation of neuron growth control mechanisms. We discovered an unexpected phenotype of reduced pain sensitivity in an importin knockout mouse line. Most strikingly, acute knockdown of this specific importin gene had an ameliorating effect in the chronic stage of a neuropathic pain model. Screening for drugs that might mimic this effect lead to the identification of a number of approved drugs that are candidates for repositioning as analgesics.
In this PoC we will carry out the following objectives: (1) file for IP protection on the new pain drug target and the initially identified candidate analgesics; (2) validate the new drug target and drug candidates in models of neuropathic and/or chemotherapy-induced chronic pain; (3) devise an HTS-compatible assay for future screening of additional drug leads for chronic pain; and (4) carry out additional IP protection and pre-clinical validation steps to maximize the commercialization potential of this discovery.
Fields of science (EuroSciVoc)
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
You need to log in or register to use this function
We are sorry... an unexpected error occurred during execution.
You need to be authenticated. Your session might have expired.
Thank you for your feedback. You will soon receive an email to confirm the submission. If you have selected to be notified about the reporting status, you will also be contacted when the reporting status will change.
Programme(s)
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
-
H2020-EU.1.1. - EXCELLENT SCIENCE - European Research Council (ERC)
MAIN PROGRAMME
See all projects funded under this programme
Topic(s)
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Funding Scheme
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
ERC-POC-LS - ERC Proof of Concept Lump Sum Pilot
See all projects funded under this funding scheme
Call for proposal
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
(opens in new window) ERC-2019-PoC
See all projects funded under this callHost institution
Net EU financial contribution. The sum of money that the participant receives, deducted by the EU contribution to its linked third party. It considers the distribution of the EU financial contribution between direct beneficiaries of the project and other types of participants, like third-party participants.
7610001 Rehovot
Israel
The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.